title: Cell proliferation, migration and CAM-dependent neurite outgrowth as developmental in vitro endpoints for screening teratogenic potential: Application to valproic acid and related analogues of varying potency.
abstract: The in vivo teratogenic potential of valproic acid (VPA) and related teratogenic and non-teratogenic analogues has been correlated with their effects on specific in vitro endpoints of cell proliferation, migration and CAM-dependent neurite outgrowth, as these events are common to crucial epochs of development. The (+/-)-2-n-propyl-4-pentynoic acid [(+/-)-4-yn-VPA] and S-2-n-propyl-4-pentynoic acid [S(-)-4-yn-VPA] analogues increased the incidence of neural tube defects in mouse embryos exposed to a single dose, whereas the E-2-n-propyl-2-pentenoic acid (E-2-en-VPA) analogue and R-2-n-propyl-4-pentynoic acid [R( + )-4-yn-VPA] enantiomer were without effect. VPA and related analogues tested exerted comparable G1 phase antiproliferative effects in C6 glioma and limb bud cells in a dose range of 0-3 mM; however, their relative potency did not correlate with in vivo teratogenicity. In contrast, VPA and all teratogenic analogues, at 3 mM, inhibited neuronal cell aggregation and limb bud chondrocyte differentiation in a manner that exhibited a reasonable correlation with their in vivo teratogenicity. The teratogenic S(-)-4-yn-VPA and non-teratogenic R( + )-4-yn-VPA enantiomers exhibited a differential inhibition of primary neurone outgrowth of neuntes stimulated by cell adhesion molecules [L1 and N-cadherin (NCAD)]. Half-maximal inhibition was observed at approximately 150 muM for the teratogenic S(-)-4-yn-VPA enantiomer, but not the non-teratogenic R( + )-4-yn-VPA form. These results suggest that in vitro perturbations of differentiation are likely to provide the greatest discriminatory power for in vivo teratogenicity.
authors.affiliation: Department of Pharmacology, University College, Belfield, Dublin 4, Ireland.
authors.forename: C L
authors.initials: CL
authors.lastname: Bacon
authors.forename: V
authors.initials: V
authors.lastname: Berezin
authors.forename: G
authors.initials: G
authors.lastname: Bode
authors.forename: E
authors.initials: E
authors.lastname: Bock
authors.forename: U
authors.initials: U
authors.lastname: Bojic
authors.forename: P
authors.initials: P
authors.lastname: Doherty
authors.forename: K
authors.initials: K
authors.lastname: Ehlers
authors.forename: U
authors.initials: U
authors.lastname: Ellerbeck
authors.forename: P
authors.initials: P
authors.lastname: Julien
authors.forename: A
authors.initials: A
authors.lastname: Kawa
authors.forename: T E
authors.initials: TE
authors.lastname: Maar
authors.forename: H
authors.initials: H
authors.lastname: Nau
authors.forename: R
authors.initials: R
authors.lastname: Pirovano
authors.forename: C M
authors.initials: CM
authors.lastname: Regan
authors.forename: A
authors.initials: A
authors.lastname: Schousboe
authors.forename: F
authors.initials: F
authors.lastname: Spezia
authors.forename: F S
authors.initials: FS
authors.lastname: Walsh
authors.forename: E J
authors.initials: EJ
authors.lastname: Williams